Innovation Pharma’s COVID-19 drug candidate Brilacidin among top three percent predicted most effective against SARS-CoV-2
On Mar. 10, 2021, Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report that a Machine…
-
-
Agilent completed CE-IVD registration of qRT-PCR In vitro diagnostic kit for SARS-CoV-2 RNA detection
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
-
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
-
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
-
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
-
NIH launched last phase 3 clinical trial to evaluate safety and effectiveness of blood thinners in adults with COVID-19
On Mar. 8, 2021, the National Institutes of Health (NIH) announced that it had launched the last of…
-
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
-
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
-
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
-
Baxter and Moderna announced agreement for manufacturing of Moderna COVID-19 vaccine in the US
On Mar. 8, 2021, Baxter and Moderna announced that they had entered into an agreement for Baxter BioPharma…
-
Moderna announced supply agreement to provide 13 million doses of COVID-19 vaccine to the Philippines
On Mar. 6, 2021, Moderna announced a supply agreement with the Government of The Philippines for 13 million doses…
-
Adaptive Biotechnologies announced FDA EUA for T-Detect COVID to confirm prior COVID-19 infection
On Mar. 5, 2020, Adaptive Biotechnologies announced that the U.S. Food and Drug Administration (FDA) had issued an…
-
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
-
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled…
-
FDA issued authorization for first molecular non-prescription, at-home test
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
-
Moderna announced NDA submitted to import and distribute Moderna’s COVID-19 vaccine candidate in Japan
On Mar. 5, 2021,Takeda Pharmaceutical announced that it has submitted a New Drug Application to the Government of…
-
Washington State Department of Health provided next-generation genome sequencing
On Mar. 4, 2021, the Washington State Department of Health announced contracts with virology labs at the University…
-
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
-
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
-
Luminex received FDA Emergency Use Authorization and CE Mark for expanded NxTAG panel test Including SARS-CoV-2
On Mar. 4, 2021, Luminex announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
-
Pfizer-BioNTech’s COVID-19 vaccine arrived in Rwanda
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
-
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 3, 2021, MediciNova announced an update on the development of a SARS-CoV-2 vaccine for COVID-19. MediciNova…
-
Biden administration announced collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines
On Mar. 2, 2021, Biden invoked the Defense Production Act to equip two Merck facilities to the standards necessary…
-
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
-
Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
-
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the National Institutes of Health (NIH), announced that it had launched a research effort…
-
First COVID-19 COVAX vaccine doses administered in Africa
On Mar. 1, 2021, the World Health Organization (WHO) announced that the first COVID-19 vaccination campaigns in Africa using…
-
Colombia received the first vaccines arriving in the Americas through COVAX
On Mar. 1, 2021, Colombia became the first country in the Americas to receive COVID-19 vaccines through the…
-
COVID-19 can kill heart muscle cells, interfere with contraction
On Mar. 1, 2021, a study from Washington University School of Medicine in St. Louis provided evidence that…
-
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
